507 results about "Dialysis membranes" patented technology

Systems and methods for the performance of kidney replacement therapy having or using a dialyzer, control components, sorbent cartridge and fluid reservoirs configured to be of a weight and size suitable to be worn or carried by an individual requiring treatment are disclosed. The system for performing kidney replacement therapy has a controlled compliance dialysis circuit, where a control pump controls the bi-directional movement of fluid across a dialysis membrane. The dialysis circuit and an extracorporeal circuit for circulating blood are in fluid communication through the dialysis membrane. The flux of fluid moving between the extracorporeal circuit and the dialysis circuit is modified by the rate at which the control pump is operating such that a rate of ultrafiltration and convective clearance can be controlled. The system provides for the monitoring of an inlet and outlet conductivity of the sorbent cartridge to provide a facility to quantify or monitor the removal of urea by the sorbent cartridge.

Apparatuses, systems, and methods for the performance of kidney replacement therapy having or using a dialyzer, control components, sorbent cartridge, and fluid reservoirs configured to be of a weight and size suitable to be worn or carried by an individual requiring treatment are disclosed. The system has a controlled compliance dialysis circuit, where a control pump controls the bi-directional movement of fluid across a dialysis membrane. A first sorbent cartridge is provided for use in a portable treatment module having activated carbon and zirconium oxide. The system also provides for the monitoring of an inlet and outlet conductivity of a sorbent cartridge containing urease to provide a facility to quantify or monitor the removal of urea by a detachable urea removal module.

A novel sleep regulating pharmaceutical formulation is introduced, typically implementing two principal drugs having actions which are reversive to one another, yet incorporated into a unitary solid dosage, and prepared for oral administration before bedtime. Usually, structure is configured to initially release a calmative or other sleep-compatible substance by prompt dissolution. The initial release is followed by a specific period of delay, which in basic formulations entails no release of any drug, and which allows a nominal interval of sleep. At the terminus of the delay, a final agent is released to induce wakeup. Incorporation of agents of opposite action within a unitary dosage form renders utility which is uniquely appropriate to the invention. In a preferred embodiment, delay of release and final delivery of wakeup agent are arranged by a dialysis membrane which eventually bursts as a result of osmotic pressure generated by a hydrophilic core.

The present invention relates to a method of treating anemia especially in an EPO resistant hemodialysis patient, comprising hemodialysis with a high cut-off dialysis membrane, wherein the hemodialysis membrane is characterized in that it has a molecular weight cut-off in water, based on dextran sieving coefficients, of between 90 and 200 kD and a molecular weight retention onset in water, based on dextran sieving coefficients, of between 10 and 20 kD, and a ΔMW of between 90 and 170 kD. The invention further relates to a high cut-off hemodialysis membrane for the treatment of anemia in hemodialysis patients, especially EPO resistant hemodialysis patients.

The present invention is related to hemodialysis, and more particularly, to a dialyser with improved efficiency of mass transfer across a dialysis membrane utilizing microchannel separation provided in accordance with embodiments of the present invention. In accordance with an embodiment, a dialyzer is provided comprising a plurality of semipermeable membrane sheets and a plurality of flow separators. The membrane sheets and flow are arranged in alternating configuration and coupled into a laminae stack defining a plurality of parallel microchannel layers. Each microchannel layer comprises a plurality of first microchannels and a plurality of second microchannels. The first and second microchannels of each microchannel layer are in fluid communication with each other via one of the plurality of membrane sheets therebetween. The MECS dialyzer is characterized as having a high surface to volume ratio and a high mass transfer coefficient.

Consuming water with increased hydrogen content can provide clinical benefits to humans and animals through a non-mitochondria alternative cellular energy (ACE) pathway and also as an antioxidant. This application discloses that the hydrogen content of drinking water can be safely increased by placing into the water a hydrogen generating device, such as a mixture of metallic magnesium and EH-101 (HB-101) containing solution, whereby the device allows for the selective passage of the generated hydrogen but restricts the passage of magnesium and EH-101 (HB-101) components. This partitioning of hydrogen from EH-101 (HB-101) components is achieved by using either reverse osmosis membrane, low density plastic material such as polyvinylidene chloride (PVDC or Saran), or low molecular weight cutoff dialysis membrane to create a sealed container of the magnesium and magnesium chloride, that can be placed into drinkable water. The EH-101 (HB-101) can be initially placed into a breakable inner compartment within the hydrogen permeable container. This compartment can be easily broken by simple squeezing just prior to placing the device into the water that is intended to have its hydrogen content increased. The increased hydrogen content can be assessed by the capacity of the water to decolorize a potassium permanganate test sample.

Sorbent cartridges having a polystyrene sulfonate resin saturated with calcium ions for the performance of kidney replacement therapy are disclosed. Systems and methods having or using a sorbent cartridge, a dialyzer, control components, a cartridge having a polystyrene sulfonate resin, and fluid reservoirs configured to be of a weight and size suitable to be worn or carried by an individual requiring treatment are disclosed. A system for performing kidney replacement therapy has a controlled compliance dialysis circuit, where a control pump controls the bi-directional movement of fluid across a dialysis membrane. The system provides for the monitoring of an inlet and outlet conductivity of the sorbent cartridge to quantify or monitor the removal of urea by the sorbent cartridge.

The invention relates to a preparation method for a zinc ion-doped yellow fluorescent carbon quantum dot. The preparation method comprises the following specific steps: placing a zinc source, a carbon source, a passivator and an organic solvent in a hydrothermal kettle, placing the hydrothermal kettle into a drying oven and heating for reaction; stopping heating after completion of reaction, cooling and taking out a solution in the hydrothermal kettle; centrifuging, taking supernatant, and carrying out rotary evaporation or drying so as to obtain solid powder, and after the solid powder is dissolved in water in an ultrasonic manner, dialyzing through a dialysis membrane so as to obtain a quantum dot aqueous solution. The characteristics that the reaction conditions are mild and the method is simple and easy to implement are realized. The prepared yellow fluorescent carbon quantum dot with high strength can stably emit yellow fluorescence and the quantum yield is high.

The invention discloses a preparation method of an anticoagulation polylactic acid hemodialysis membrane. Cellulose acetate membranes and polysulfone membranes are widely used in current clinical application. Poly lactic acid has a good membrane-forming property, but is inclined to hydrophobicity, and blood contacting materials are often required to have good hydrophilicity, can reduce the protein adsorption on material surfaces and reduce platelet aggregation. In the preparation method, firstly a polylactic acid hollow fiber membrane with epoxy groups is prepared by a one-step method, then diamine activation of the polylactic acid hollow fiber membrane is carried out, finally heparin is introduced into the activated polylactic acid hollow fiber membrane to obtain the anticoagulation polylactic acid hemodialysis membrane. In the preparation method, the polylactic acid is used as a dialysis membrane material, and the novel dialysis membrane is prepared through use of the wet/dry solution spinning method; and through in-situ polymerization of monomers having double bonds and the epoxy groups, groups of high reaction activity are introduced into a polylactic acid matrix, and reaction conditions of subsequent diamine grafting process and heparin fixing process are mild, so the method is a simple and convenient modification method.

This invention provides a micro flow control chip formed by three sealed parts integrating the dialyzing functions. The top and bottom layers of the chip have channels for microfluid and the sandwich layer is a dialysis membrane. The preparation method includes three steps: first of all, casting the upper and lower PDMS layer to be aggregated in a bake oven for 20-60min to be stripped from the form board, a small hole on the top is opened for the fluid enter then the dialysis membrane is stuck at a suitable place of the bottom PDMS to be adhered closely with the top to align the two layers of channels accurately, finally, the total chip is aggregated for 1~3h in a bake oven, the chip is always sealed.

The invention discloses a spiral coil type diffusion dialysis membrane assembly and a preparation method thereof. The spiral coil type diffusion dialysis membrane assembly is characterized in that an ion exchange membrane is clamped between two central tubes, runner screens on two sides mutually and tightly adhere for surrounding the central tubes to coil together according to same direction and are stuck on the axial edge to be sealed into a cylinder; the tail end of the ion exchange membrane forms two tangential runner openings which are radially symmetrical on the outer edge of the cylinder, and a side flow tube is sticked, sealed and fixed respectively by two openings; then the whole cylinder including the side flow tube is tightly wound and fixed by a plastic membrane to form a membrane core, the membrane core is put into a cylindrical shell, and two tips are cast and fixed by adhesive to form the spiral coil type diffusion dialysis membrane assembly with four inlet and outlet adapters. The equipment is compact, has big packing density, can be vertically assembled to occupy small space, can realize the radial spiral counter flow of diffusion liquid and dialysate flow, has big turbulence degree, high mass transfer efficiency and large feed liquid treatment capacity on unit membrane area and is easy to integrate with other reaction or separation equipment.

A microdialysis probe comprises a tubiform probe body, a tubiform dialysis membrane disposed distally of the probe body, and flexible conduits for adducing and abducing dialysis fluid, distal end portions of which are disposed in the probe body. Apart from the conduit portions disposed externally of the probe body the probe is substantially rotationally symmetrical. One of the conduits, preferably the abducing conduit, comprises an S-shaped portion inside of the probe, adjacent to the distal end of the other conduit. Also disclosed is an assembly of the probe and a cannula for inserting it into tissue; after insertion the cannula can be withdrawn in a proximal direction.

The invention discloses a citric acid-chitosan-modified anticoagulation polyurethane blood dialysis membrane and a preparation method thereof. The membrane is of a hollow fibrous structure, and the inner surface and outer surface are dense cortical layers, and the middle is a porous supporting layer, so that the blood dialysis membrane is high in permeability and separating property and antibacterial property; the inner diameter is 160 to 250mu m; the membrane thickness is 30 to 50 mu m, and the ultrafiltration coefficient is 7.0 to 60 ml/m<2>.h.mmHg; citric acid-chitosan-modified anticoagulation polyurethane is taken as membrane materials, and in membrane solution, the percentage mass content of the modified anticoagulation polyurethane is 15 to 30%, and the percentage mass content of a solvent is 70 to 85%, and the blood dialysis membrane is prepared by using a nonsolvent induced phase separation method. The preparation process of the dialysis membrane is simple and easy to control, and the prepared membrane has good anticoagulant activity, biocompatibility and antibacterial property, and the clearance rates of urea, beta2-microglobulin and albumin are respectively 55 to 80%, 48 to 60%, and 2.5 to 9%, and the rate of resisting pathogenic escherichia coli is 99%.

A microdialysis probe includes a dialysis membrane located and supported between a closed distal end of the probe and a proximal end of the same, the membrane essentially surrounding a space for passage of perfusion liquid. The probe has an inlet and outlet for perfusion liquid, where a position indicating object at the distal part of the probe allows non-invasive examination of the location of the distal part of the microdialysis probe.